Evidence map›Paper›PMID 39231667›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Effectiveness of Additional Immunosuppressive Drugs for Corticosteroid-refractory Immune Checkpoint Inhibitor-induced Myocarditis: Two Case Reports.

Hiroyuki Sakaguchi, Shigeki Nanjo, Shigeki Sato, Hiroshi Kotani, Akihiro Nishiyama, Kaname Yamashita, Koushiro Ohtsubo, Chiaki Suzuki, Masaya Shimojima, Seiji Yano and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hiroyuki SakaguchiDepartment of Medical Oncology, Kanazawa University Hospital, Japan.
Shigeki NanjoDepartment of Respiratory Medicine, Kanazawa University Hospital, Japan.
Shigeki SatoDepartment of Medical Oncology, Kanazawa University Hospital, Japan.
Hiroshi KotaniDepartment of Medical Oncology, Kanazawa University Hospital, Japan.
Akihiro NishiyamaDepartment of Medical Oncology, Kanazawa University Hospital, Japan.
Kaname YamashitaDepartment of Medical Oncology, Kanazawa University Hospital, Japan.
Koushiro OhtsuboDepartment of Medical Oncology, Kanazawa University Hospital, Japan.
Chiaki SuzukiDepartment of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kyoto University, Japan.
Masaya ShimojimaDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Japan.
Seiji YanoDepartment of Respiratory Medicine, Kanazawa University Hospital, Japan.
Shinji TakeuchiDepartment of Medical Oncology, Kanazawa University Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) improve the outcomes of several types of cancer. However, they are also associated with various immune-related adverse events including myocarditis. ICI-induced myocarditis is a rare, potentially life-threatening adverse event. We herein report two cases of corticosteroid-refractory ICI-induced myocarditis. In both cases, additional immunosuppressive therapies, such as intravenous immunoglobulin and tacrolimus, successfully resolved myocarditis. Given the corticosteroid-refractory nature of these cases, we suggest that prompt addition of other immunosuppressive drugs to corticosteroid therapy should be considered in the treatment of ICI-induced myocarditis.

Indexed as

Adrenal Cortex HormonesImmune Checkpoint InhibitorsImmunosuppressive AgentsMyocarditisTacrolimusHumansImmunoglobulins, IntravenousTreatment OutcomeAdrenal Cortex HormonesImmune Checkpoint InhibitorsImmunoglobulins, IntravenousImmunosuppressive AgentsTacrolimusirAEsIVIGmyocarditistacrolimus

Identifiers

PMID39231667
PMCPMC12097839

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.